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Summary
Background: Streptococcus gallolyticus bacter-
aemia has been associated with several pathologies,
including bacterial endocarditis and colorectal
cancer.
Aims: In this study, we have analysed whether
Streptococcus gallolyticus bacteraemia is associated
with an increased risk of hepatobiliary and colonic
pathology. The association with other pathologies
and the antibiotic sensitivities of Streptococcus
gallolyticus were also analysed.
Design: Observational retrospective study.
Methods: The case notes of patients with docu-
mented Streptococcus gallolyticus bacteraemia be-
tween 2007 and 2012 at Mater Dei hospital (Malta)
were reviewed. Demographic and clinical data,
including co-morbidities, clinical investigations,
antibiotic sensitivities and mortality were analysed.
Results: A total of 42 patients (33 males, 9 females)
were recruited. Two patients were pre-term infants
and were therefore excluded from the study. Mean
age of the cohort population studied was 72 years
(SD 14). One-year survival rate was 62%.
Gastrointestinal (colonic and hepatobiliary–
pancreatic) pathologies were present in 59.5% of
patients with 16% of this group having more than
one gastrointestinal pathology. High incidence rates
of underlying diabetes mellitus (28.6%), valvular
heart disease (21.4%) and malignancies (21.4%)
were noted in this study. Furthermore, we observed
that 14.3% of patients had an underlying respiratory
pathology. Streptococcus gallolyticus was 100%
sensitive to cefotaxime and vancomycin but was
highly resistant to clindamycin, erythromycin and
tetracycline.
Conclusions: Streptococcus gallolyticus bacter-
aemia is commoner in the elderly and in those
with multiple underlying co-morbidities. The high
incidence of gastrointestinal pathologies among pa-
tients with Streptococcus gallolyticus bacteraemia
(59.5%) suggests that a thorough work-up for
colonic and hepatobiliary/pancreatic pathology
should be carried out in these patients.
Introduction
In modern literature, Streptococcus gallolyticus is
used interchangeably with Streptococcus bovis.
In this study, we decided to use the term
Streptococcus gallolyticus to refer to all subtypes
of Streptococcus bovis. Streptococcus gallolyticus
forms part of the normal flora of the alimentary
tract. Faecal carriage of Streptococcus gallolyticus
in normal colons ranges from 2.3% to 13.0%.1–3 It
is also commonly found in the alimentary tract of
cows, sheep and other ruminants.4–6 Some studies
have demonstrated a significantly higher carriage
rate of Streptococcus gallolyticus in patients suffer-
ing from colorectal cancer when compared with
controls.1,2 However, there are also data showing
no increase carriage rate when compared with con-
trols in patients suffering from colorectal cancer3 or
colorectal adenomatous polyps.7 It is a catalase
negative and oxidase-negative, non-motile, non-
sporulating, non-beta-haemolytic Gram-positive
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lactic acid bacterium that grows as pairs or chains of
cocci.8
The incidence of colorectal cancer with
Streptococcus gallolyticus endocarditis or bacter-
aemia has been reported to vary from 6% to
80%.9–11 Colonic neoplasia may arise years after
the presentation of Streptococcus gallolyticus
bacteraemia or infectious endocarditis.12 The
association between serological positivity for
Streptococcus gallolyticus and colorectal cancer is
still controversial though studies have shown higher
levels of IgG antibodies against Streptococcus
gallolyticus in colorectal cancer patients than in
controls.13–16 However, there has been no differ-
ence between Streptococcus gallolyticus IgM
levels in colorectal cancer patients and controls,
thus suggesting the role of chronic bacterial inflam-
mation in colonic cancer.
The link between Streptococcus gallolyticus and
adenomatous polyps has been described in the lit-
erature, though in small studies, case series and case
reports.16–19 In a study in rats, Streptococcus infan-
tarius subsp. infantarius or its antigens promoted the
progression of pre-neoplastic lesions through
increased formation of hyper-proliferative aberrant
colonic crypts, enhanced expression of proliferative
markers and increased production of IL-8 in the
colonic mucosa.20
Streptococcus gallolyticus is the second greatest
cause of endocarditis from streptococci, being
responsible for 5–25% of all patients with bacter-
ial endocarditis.21–23 The mortality rate of
Streptococcus gallolyticus endocarditis is estimated
to be 2–4%. Streptococcus gallolyticus has also
been linked mildly to other benign conditions such
as diverticulosis and inflammatory bowel disease.24
Patients with underlying liver cirrhosis may also be
at an increased risk of suffering from Streptococcus
gallolyticus bacteraemia.25 The most commonly
associated organisms include Streptococcus infan-
tarius (biotype II/1) and Streptococcus gallolyticus
subsp. pasteurianus (biotype II/2).26 The reason is
possibly due to increased permeability of the intes-
tinal wall, impaired bacterial clearance and
decreased motility of the gastrointestinal tract, thus
promoting the translocation of bacteria across the
intestinal wall.27
In this study, we have analysed whether
Streptococcus gallolyticus bacteraemia is associated
with an increased risk of hepatobiliary and colonic
pathology. The association with other pathologies
and the antibiotic sensitivities of Streptococcus gal-
lolyticus were also analysed.
In modern literature, Streptococcus gallolyticus is
used interchangeably with Streptococcus bovis.
In this study, we decided to use the term
Streptococcus gallolyticus to refer to all subtypes
of Streptococcus bovis.
Methods
All patients with Streptococcus gallolyticus bacter-
aemia admitted to Mater dei Hospital (Malta) be-
tween January 2007 and December 2012 were
included in the study. The pathology department
at our centre identifies Streptococcus gallolyticus
by carrying out the following tests:
(i) Gram stains on cultures grown on blood agar
(Streptococcus gallolyticus forms Gram-positive
cocci in chains).
(ii) Catalase test (Streptococcus gallolyticus is catalase
negative).
(iii) Vitek GP (This is a card that helps to identify Gram-
positive bacteria and helps identify the subspecies of
Streptococcus gallolyticus).
(iv) ATB strep (a strip for the antibiogram).
The case notes of patients were reviewed after
obtaining data protection clearance and ethical
board approval. The following data were retrieved:
 Demographic data;
 Clinical data including underlying medical patholo-
gies, investigations performed and results;




Statistics were calculated using SPSS version 19
and Microsoft Excel 2010.
Results
Forty-two patients (33 males) were recruited. A fur-
ther two patients (4.76%) were preterm infants and
were therefore excluded from the study. The mean
age of the cohort studied was 72 years (SD 14;
interquartile range: 18; range: 41–97 years).
Sixteen patients (38.04%) were between 41 and
70 years. Twenty-three (55%) patients were above
the age of 71 whereas one patient (2.38%) was
above the age of 91 years. Four cases were reported
in 2007, 2008 and 2010, respectively, whereas
11 cases were diagnosed in 2009 and 2011. Eight
cases of Streptococcus gallolyticus bacteraemia
were diagnosed in 2012.
Thirty-day survival rate was 83% and 1-year sur-
vival rate was 62%. There was 50% survival of
patients at 5.35 years as shown in the Kaplan–
Meier curve (Figure 1).
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Colonic pathologies
Fifteen patients (35.7%) had significant colonic
pathology. Six patients (14.3%) had adenomatous
polyps, whereas two patients (4.76%) had colorectal
cancer. Thus, 19% of patients had colonic aden-
omas or colonic adenocarcinoma. The polyps that
were included were adenomas with a minimum
diameter of 10mm and had tubulovillous or villous
histological findings, with dysplasia. One of these
patients also had chronic hepatitis B without evi-
dence of cirrhosis. Seven patients (16.7%) had
extensive diverticular disease (in five patients this
was the only significant finding present). Two pa-
tients had underlying inflammatory bowel disease
(ulcerative colitis).
Hepatobiliary–pancreatic pathologies
Eleven patients (27.5%) were diagnosed
with hepatobiliary–pancreatic pathologies.
Choledocolithiasis or cholelithiasis with cholangitis
or cholecystitis was present in four patients. One of
these patients also had multiple other pathologies
including renal cell carcinoma, congestive heart
failure, diverticular disease and myelofibrosis.
Two patients had a pancreatic carcinoma, one
patient had chronic hepatitis C and two patients
had cirrhosis secondary to autoimmune hepatitis.
One of these patients was being treated with
azathioprine. Cirrhosis secondary to non-alcoholic
steatohepatitis (NASH) and cirrhosis secondary to
idiopathic cirrhosis were documented in two other
patients.
Immunosuppression
Five patients (12%) were immunosuppressed. One
patient had multiple myeloma and was receiving
chemotherapy. Another patient had large B-cell
lymphoma and another patient had underlying
myelofibrosis. Two other patients were being treated
with azathioprine for ulcerative colitis and for auto-
immune hepatitis, respectively. The latter patient
also had congestive cardiac failure as a significant
co-morbidity.
Respiratory and urinary pathologies
Four patients (9.52%) with Streptococcus gallolyti-
cus bacteraemia were admitted to hospital with a
pneumonia. One of these patients had congestive
cardiac failure as a medical co-morbidity. Two pa-
tients (4.76%) admitted with infective exacerbation
of chronic obstructive pulmonary disease were also
found to have Streptococcus gallolyticus bacter-
aemia. Another four patients (9.52%) had urinary
sepsis. Two of these had congestive cardiac failure.
Other co-morbidities
One patient had an underlying metastatic squamous
cell carcinoma of the skin, with diabetes mellitus
and congestive heart failure as other co-morbidities.









































Figure 1. Kaplan–Meier survival curve for patients with Streptococcus gallolyticus bacteraemia.
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malignancies (one patient—multiple myeloma,
one patient—B-cell lymphoma, one patient—
myelofibrosis).
Ten patients (24%) had underlying congestive car-
diac failure with most of them having several co-
morbidities including peripheral vascular disease,
cerebrovascular disease and renal impairment.
Eleven patients (26%) had underlying diabetes
mellitus and nine patients (21.4%) had underlying
valvular heart disease.
Bacterial endocarditis
Bacterial endocarditis was diagnosed in eight
patients (19.0%), three of whom (37.5%) had
underlying valvular heart disease, with two patients
having undergone prosthetic valve replacements.
Three patients with bacterial endocarditis had
underlying adenomatous polyps at colonoscopy
and another patient had malignancy of the sigmoid
colon. Hepatitis C was an underlying co-morbidity
in a patient diagnosed with Streptococcus gallolyti-
cus bacteraemia.
A summary of the patients’ conditions can be
found in (Table 1).
Antibiotic sensitivity profile
In this study, Streptococcus gallolyticus was 100%
sensitive to cefotaxime and vancomycin, with 88%
sensitivity to levofloxacin and chloramphenicol and
79% sensitivity to penicillins. However, we found
an increased resistance to clindamycin (33.3%),
erythromycin (50.0%) and tetracycline (73.8%)
(Table 2).
Discussion
Streptococcus gallolyticus forms part of the normal
intestinal microflora. The stool carriage rates in neo-
nates have been reported to be 28%, whereas in
adults it varies from 2.3% to 13%.1,2,3,28
Our study showed a rising trend of Streptococcus
gallolyticus in recent years. A rising trend in
Streptococcus gallolyticus as a cause of infective
endocarditis was also reported in France.21,23
Gastrointestinal pathologies were present in
59.5% of patients. Significant colonic pathology
was present in 35.7% thus emphasizing the need
for a colonoscopy or CT colonography in patients
with Streptococcus gallolyticus bacteraemia.
Colonic cancers or adenomatous polyps were pre-
sent in 19% of patients which is lower than the pre-
viously reported rates of 25–80%.29 Meanwhile, the
reported incidence of colon cancer in males in 2012
where Malta has a slightly higher incidence (60.1 in
males; 37.6 in females per 100 000 patients) when
compared with the rest of Europe (55.7 in males and
34.6 in females per 100 000 patients).30
Thus, the diagnosis of underlying Streptococcus
gallolyticus bacteraemia may provide an early op-
portunity for screening patients and detecting co-
lonic lesions at a precancerous stage. Colorectal
cancer may appear years after the diagnosis of
Streptococcus gallolyticus bacteraemia.13
Mechanisms by which Streptococcus gallolyticus
can lead to colonic malignancies have been studied.
In laboratory experiments, the binding of
Streptococcus bovis extracted antigens to colon
cancer cells stimulated the production of inflamma-
tory cytokines and the overexpression of cyclooxy-
genase-2 (COX-2). COX-2, via prostaglandins,
promotes cellular proliferation and angiogenesis
and inhibits apoptosis thus playing a role in cancer
formation.31,32
Histone-like protein A of Streptococcus gallolyti-
cus has been identified to bind to heparan sulphate
proteoglycans-expressing colon tumour cell lines.33
Streptococcus gallolyticus can cause bacterial endo-
carditis by binding to collagen type I most com-
monly but also collagen type IV, fibrinogen,
collagen type V and fibronectin.34
Beside the characteristic adhesive traits of
Streptococcus gallolyticus to the intestinal cells, it
is also able to grow in bile.35 This enables it to
bypass the hepatic reticulo-endothelial system and
access systemic circulation easily.12 This might ex-
plain the route responsible for colonic pathology.
Furthermore, its ability to survive in bile may be re-
sponsible for biliary sepsis especially in the presence
of pre-existing biliary tract disease. In our study,
9.5% of patients had sepsis secondary to gallstones.
Streptococcus gallolyticus bacteraemia also tends to
affect patients who are elderly and immunocom-
promised and with multiple underlying co-
morbidities.36
The incidence of infective endocarditis in those
patients with underlying adenomatous polyps or co-
lonic cancer was 50% (four out of eight patients with
adenomatous polyps and colorectal cancer). An in-
cidence of between 6% and 80% of infective endo-
carditis with underlying adenomatous polyps and
colorectal cancer is reported in the literature.10
The incidence of infective endocarditis (11.8%; 4
out of 34 patients) was much higher than in the
rest of the cohort (without underlying colonic aden-
omas and colorectal cancer).11
Ten (23.8%) of our patients had underlying solid
organ (non-colonic) and haematological malig-
nancies. In the literature, this was reported to vary
between 15% and 32%.37,38 In a study by
Corrediora et al., the association of Streptococcus
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gallolyticus with non-colonic cancer was 6% vs.
57% for Streptococcus infantarius (P<0.0001).39
Out of five patients who were immunosuppressed
and developed the infection, two of them were
being administered azathioprine. This is an im-
munosuppressive pro-drug that is converted into
6-mercaptopurine in the body thus blocking purine
metabolism and DNA synthesis. It is known to
increase the risk of fungal, protozoal, viral and
uncommon bacterial infections.40
We had an incidence of 14.3% of respiratory
pathologies in those with underlying Streptococcus
gallolyticus bacteraemia. This value was not signifi-
cantly different from the presence of colorectal
cancer and colorectal adenomas in our study
group, which to date has been more of an estab-
lished association. These are the first data in the lit-
erature showing this occurrence. Future studies may
be aimed to determine if there is a true association
between respiratory pathologies and Streptococcus
gallolyticus bacteraemia.
In our study, the incidence of diabetes mellitus
was 26% similar to 24% reported in the literature.41
Patients with underlying diabetes mellitus have a
higher incidence of infection and a worse out-
come.42,43 Rising trends in the incidence of diabetes
mellitus in Malta might be responsible for the rising
trends in Streptococcus gallolyticus bacteraemia in
over recent years.
High incidence rates of valvular heart disease
(21.4%) and underlying malignancies (21.4%)
were also noted in this study. Malignancies included
colonic (two patients), renal cell (one patient),
pancreatic (two patients) and haematological
Table 1 A summary of patient observations in this study
Observation Number of patients % of patients
Colonic pathologies
Adenomatous polyps 6 14.30
Colorectal cancer 2 4.76
Diverticular disease 7 16.70
Inflammatory bowel disease 2 4.76
Hepatobiliary/pancreatic pathologies
Choledocolithiasis/cholelithiasis 4 9.52
Pancreatic carcinoma 2 4.76
Chronic hepatitis C 1 2.38
Cirrhosis secondary to autoimmune hepatitis 2 4.76
Cirrhosis secondary to NASH 1 2.38
Cirrhosis secondary to idiopathic cirrhosis 1 2.38
Immunosuppressed patients 5 12.00
Respiratory pathologies
Pneumonia 4 9.52
Infective exacerbation of chronic obstructive pulmonary disease 2 4.76
Urinary sepsis 4 9.52
Malignancies
Squamous cell carcinoma 1 2.38
Haematological malignancies 3 7.14
Pancreatic carcinoma 2 4.76
Cardiac pathologies
Underlying valvular heart disease 9 21.40
Congestive heart failure 10 24.00
Bacterial endocarditis 8 19.00
Diabetes mellitus 11 26.00
Table 2 Antibiotic sensitivity profile
Type of antibiotic Sensitive Resistant Intermediate
Penicillin 33 (78.6) 0 9 (21.4)
Chloramphenicol 37 (88.1) 0 5 (11.9)
Cefotaxime 42 (100) 0 0
Vancomycin 42 (100) 0 0
Clindamycin 28 (66.7) 14 (33.3) 0
Levofloxacin 37 (88.1) 1 (2.38) 4 (9.52)
Erythromycin 21 (50.0) 21 (50.0) 0
Tetracycline 11 (26.2) 31 (73.8) 0
Values in parentheses are percentages.
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malignancies (three patients) and one metastatic
squamous cell cancer.
The retrospective nature of this study is an import-
ant limitation. However, our cohort represents one
of the largest group of patients which have been
extensively investigated and followed up for differ-
ent pathologies. Furthermore, our study also gives
important information about antibiotic susceptibility
and resistance.
Conclusions
Streptococcus gallolyticus bacteraemia is more
common in the elderly and in those with multiple
underlying co-morbidities. The high incidence of
gastrointestinial pathologies (59.5%) in these pa-
tients suggests that all patients with Streptococcus
gallolyticus should undergo a thorough colonic
and hepatobiliary–pancreatic assessment. The pres-
ence of any underlying malignancy should also be
sought. The association of respiratory pathologies
needs to be further evaluated in future studies.
Conflict of interest: None declared.
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